Cannabis Bioscience International Holdings is an early-stage company operating in three businesses: clinical trial services, cannabis education, and CBD consumer products. The only revenue-generating business today is Alpha Research Institute, a clinical research organization (CRO) based in Houston that serves as a trial site for pharmaceutical companies and larger CROs. Alpha Research recruits patients, conducts trials, and reports results across a broad range of therapeutic areas. Clients have included Pfizer, Merck, Novartis, and major CROs like IQVIA and Parexel. The other two businesses are largely non-operational: Pharmacology University offers cannabis industry training, certifications, and digital content but generated no revenue in FY25, and VitaCookies — a planned line of CBD-infused functional cookies targeting conditions like anxiety and chronic pain — has not yet launched. Total company revenue was $303K in FY25, almost entirely from Alpha Research, and two customers accounted for roughly 91% of that revenue. The company's stated strategy is to evolve into an integrated cannabis biotech platform by expanding into cannabinoid-specific trials where it would act as Sponsor rather than just a site, commercializing proprietary CBD formulations backed by 10 utility patent applications, reviving Pharmacology University, and launching VitaCookies in Texas. The VitaCookies national rollout is constrained by the FDA's current position that CBD cannot be added to food in interstate commerce. The company has only two full-time employees and relies heavily on contractors.